Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni,

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series

Volume 61, Issue 3, Pages (March 2012)

Volume 62, Issue 3, Pages (September 2012)

Volume 51, Issue 2, Pages (February 2007)

Volume 62, Issue 4, Pages (October 2012)

Epidemiology and Risk Factors of Urothelial Bladder Cancer

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

European Urology Oncology

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 60, Issue 5, Pages (November 2011)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 51, Issue 3, Pages (March 2007)

Volume 73, Issue 3, Pages (March 2018)

European Urology Oncology

Volume 70, Issue 4, Pages (October 2016)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Volume 63, Issue 6, Pages (June 2013)

Volume 56, Issue 3, Pages (September 2009)

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 4, Pages (April 2013)

Volume 62, Issue 6, Pages (December 2012)

European Urology Oncology

Nomograms for Bladder Cancer

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 5, Pages (November 2015)

Volume 52, Issue 5, Pages (November 2007)

Volume 74, Issue 2, Pages (August 2018)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

European Urology Oncology

Stephen B. Williams, Ashish M

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL,

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 1, Pages (January 2017)

Volume 59, Issue 1, Pages (January 2011)

Volume 60, Issue 6, Pages (December 2011)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 56, Issue 5, Pages (November 2009)

National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 50, Issue 2, Pages (August 2006)

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

European Urology Oncology

Prostate Cancer Nomograms: An Update

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.

European Urology Oncology

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

European Urology Oncology

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 50, Issue 5, Pages (November 2006)

European Urology Oncology

The role of antimalarial treatment in the elimination of malaria

Volume 54, Issue 1, Pages (July 2008)

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

European Urology Oncology

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci V. Sakka, S. Tsiodras, L. Galani, A. Antoniadou,

Volume 51, Issue 2, Pages (February 2007)

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

European Urology Oncology

European Urology Oncology

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Presentation transcript:

Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni, Zhe Tian, Denis Soulières, Emanuele Montanari, Dario Ratti, Pietro Acquati, Alberto Briganti, Shahrokh F. Shariat, Firas Abdollah, Luca Carmignani, Pierre I. Karakiewicz European Urology Oncology Volume 1, Issue 4, Pages 346-351 (September 2018) DOI: 10.1016/j.euo.2018.05.008 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Smoothed 5-yr cumulative mortality estimates for patients affected by nonmetastatic reptroperitoneal sarcoma in (A) the overall population (n=1226), (B) patients aged <62 yr (n=618), and (C) patients aged ≥62 yr (n=608). DSM=disease-specific mortality; NDSM=non-DSM. European Urology Oncology 2018 1, 346-351DOI: (10.1016/j.euo.2018.05.008) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Smoothed 5-yr cumulative mortality estimates for patients affected by nonmetastatic reptroperitoneal sarcoma with (A) liposarcoma (n=800), (B) leiomyosarcoma (n=300), (C) low-grade disease (n=605), (D) high-grade disease (n=621), (E) tumor <17cm (n=610), (F) tumor ≥17cm (n=616), (G) radiation treatment (n=372), and (H) no radiation treatment (n=854). DSM=disease-specific mortality; NDSM=non-DSM. European Urology Oncology 2018 1, 346-351DOI: (10.1016/j.euo.2018.05.008) Copyright © 2018 European Association of Urology Terms and Conditions